Daniel S. Lorrain, Chief Scientific Officer at Contineum Therapeutics, Inc. (CTNM), sold 16,248 shares at $16.03 ($260K) on 2026-02-24, disclosed to the SEC on 2026-02-26.
Open-market sale of $260k CTNM by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.03 | 4,300 | $69K | 26.5% |
| 2 | $16.03 | 4,300 | $69K | 26.5% |
| 3 | $16.01 | 3,824 | $61K | 23.5% |
| 4 | $16.01 | 3,824 | $61K | 23.5% |
| Total | $16.02 avg | 16,248 | $260K | 100% |
| Filing → |
| CTNM | SELL | 2026-06-01 | $55K | — | Filing → |
| CTNM | SELL | 2026-05-01 | $55K | — | Filing → |
| CTNM | SELL | 2026-04-06 | $56K | — | Filing → |